Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Charles River Laboratories International, Inc. Common Stock
(NY:
CRL
)
167.34
+5.25 (+3.24%)
Streaming Delayed Price
Updated: 1:59 PM EST, Nov 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Charles River Laboratories International, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Charles River Laboratories to Present at Jefferies Global Healthcare Conference
November 17, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
Drug Development Inputs & Services Stocks Q3 Teardown: Charles River Laboratories (NYSE:CRL) Vs The Rest
November 16, 2025
Looking back on drug development inputs & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.
Via
StockStory
5 Must-Read Analyst Questions From Charles River Laboratories’s Q3 Earnings Call
November 12, 2025
Charles River Laboratories’ third quarter results were met with negative market reaction, as investors focused on the company’s muted top-line growth and margin pressures. Management cited ongoing...
Via
StockStory
Topics
Earnings
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
November 11, 2025
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...
Via
StockStory
Topics
Artificial Intelligence
Stocks
3 Healthcare Stocks We Approach with Caution
November 09, 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID...
Via
StockStory
Topics
Stocks
Corporate Earnings Fuel Market Gains, But Mixed Results Hint at Underlying Volatility
November 07, 2025
Recent third-quarter (Q3) 2025 corporate earnings have painted a complex yet largely positive picture for North American equity markets. While robust performances from key sectors, particularly...
Via
MarketMinute
Topics
Artificial Intelligence
Earnings
Economy
This Charles River Laboratories Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
↗
November 06, 2025
Via
Benzinga
Robinhood To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
↗
November 06, 2025
Via
Benzinga
CRL Q3 Deep Dive: Portfolio Streamlining and End Market Stabilization Shape Outlook
November 06, 2025
Lab services company Charles River Laboratories (NYSE:CRL) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.00 billion. Its non-GAAP profit...
Via
StockStory
Charles River (CRL) Q3 2025 Earnings Transcript
↗
November 05, 2025
Charles River (CRL) Q3 2025 Earnings Transcript
Via
The Motley Fool
Charles River Beat Expectations But Why Is The Stock Falling?
↗
November 05, 2025
Charles River stock dips as Q3 revenue slips, EPS beats estimates, and company raises 2025 outlook with cost cuts and $1 billion buyback plan.
Via
Benzinga
Exploring the top movers within the S&P500 index during today's session.
↗
November 05, 2025
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via
Chartmill
Why Charles River Laboratories (CRL) Shares Are Getting Obliterated Today
November 05, 2025
Shares of lab services company Charles River Laboratories (NYSE:CRL) fell 5.8% in the morning session after the company reported third-quarter results that revealed significant underlying weaknesses.
Via
StockStory
Topics
Artificial Intelligence
Wednesday's session: gap up and gap down stock in the S&P500 index
↗
November 05, 2025
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Via
Chartmill
Charles River Laboratories (NYSE:CRL) Tops Q3 Earnings Estimates Despite Flat Revenue
↗
November 05, 2025
Charles River Labs Q3 earnings beat estimates with $2.43 EPS. The company raised its full-year EPS guidance while navigating a slight revenue decline.
Via
Chartmill
Topics
Earnings
Charles River Laboratories’s (NYSE:CRL) Q3: Beats On Revenue
November 05, 2025
Lab services company Charles River Laboratories (NYSE:CRL) announced better-than-expected revenue in Q3 CY2025, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share...
Via
StockStory
Charles River Laboratories Provides Update on Strategic Review
November 05, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Announces Third-Quarter 2025 Results
November 05, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
What To Expect From Charles River Laboratories’s (CRL) Q3 Earnings
November 03, 2025
Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results this Wednesday before market hours. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
October 27, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
October 24, 2025
From
Halper Sadeh LLC
Via
Business Wire
Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development
October 22, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities
October 20, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
Discover which S&P500 stocks are making waves on Thursday.
↗
October 16, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
Via
Chartmill
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption
October 15, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call
October 14, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
3 Reasons to Avoid CRL and 1 Stock to Buy Instead
October 14, 2025
The past six months have been a windfall for Charles River Laboratories’s shareholders. The company’s stock price has jumped 60.1%, hitting $170.64 per share. This was partly due to its solid quarterly...
Via
StockStory
Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks
October 08, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Charles River Laboratories (NYSE:CRL) and its peers.
Via
StockStory
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing
October 08, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today